The efficacy of zinc as an adjuvant therapy in the treatment of severe pneumonia in children between 2 months to 2 years of age
Abstract
Objective: To compare the efficacy of zinc as an adjuvant therapy in the treatment of severe pneumonia in children between 2 months to 2 years of age. Study Design: Case Control study. Setting: Department of Paediatrics, Mayo Hospital Lahore. Period: 20 February 2019 to 20 August 2019. Material & Methods: After approval of Institutional Review board of King Edward Medical University Lahore Pakistan total 200 cases were selected by Consecutive (non probability) sampling and were divided into 2 groups each containing 100 cases. Group A children were given 20 mg elemental zinc per day plus Ampicillin plus cloxacillin while Group B patients were given only on Ampicillin plus cloxacillin. Mean + Standard deviation were calculated for continuous variables like age, base line zinc level and duration of fever. Post stratification chi square test was applied in which P value ≤0.05 will be considered as significant value. Results: Mean Age was recorded as 09 Months ± 5.54 in Group A while in Group B it was recorded as 12 Months ± 6.47. In Group A, 56 (56%) infants showed improvement who were administered zinc while 44 (44%) did not. Similarly, in Group B, 38 (38%) infant patients showed improvement who were not administered zinc whereas 62 (62%) did not show any improvement. This improvement was statistically significant P Value = 0.010. Conclusion: This study revealed a statistically significant efficacy estimate for zinc in the resolution of severe pneumonia.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.